These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33190809)

  • 1. Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy.
    Nicosia L; Bucpapaj R; Barresi V; Damante R; Napoli G; Ghimenton C; Giaj-Levra N; Cancedda M; Flaminio S; Figlia V; Alongi F
    Neurochirurgie; 2021 Apr; 67(2):193-197. PubMed ID: 33190809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer.
    Tsutsui T; Miyashita K; Sabit H; Fukui I; Hayashi Y; Mizokami A; Ikeda H; Nagatani H; Nakada M
    World Neurosurg; 2016 Jul; 91():670.e1-6. PubMed ID: 27046016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma.
    Lee KL; Terris MK
    Urology; 2003 Aug; 62(2):351. PubMed ID: 12893358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.
    Anda T; Honda M; Ishihara T; Kamei T
    Neurol Med Chir (Tokyo); 2014; 54(4):327-30. PubMed ID: 24201100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature.
    Kessler RA; Garzon-Muvdi T; Yang W; Weingart J; Olivi A; Huang J; Brem H; Lim M
    World Neurosurg; 2017 May; 101():47-56. PubMed ID: 28143726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An unusual case of "sterile" abscess within low-grade meningioma during anti androgenic therapy and LH-releasing hormone agonist treatment for prostate cancer.
    Fabbri VP; Asioli S; Palandri G
    Clin Neurol Neurosurg; 2020 Sep; 196():105993. PubMed ID: 32563976
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
    Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
    J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
    Lawrentschuk N; Fernandes K; Bell D; Barkin J; Fleshner N
    J Urol; 2011 Mar; 185(3):848-54. PubMed ID: 21239017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.
    Moul JW; Fowler JE
    Urology; 2003 Dec; 62(6 Suppl 1):20-8. PubMed ID: 14706505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy.
    Marumo K; Baba S; Murai M
    Int J Urol; 1999 Jan; 6(1):19-23. PubMed ID: 10221860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
    Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
    Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
    van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
    Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.
    Blumberg JM; Kwon EO; Cheetham TC; Niu F; Shapiro CE; Pacificar J; Loo RK; Williams SG; Chien GW
    Urology; 2011 Feb; 77(2):412-6. PubMed ID: 21111460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
    Haliloglu A; Baltaci S; Yaman O
    J Urol; 2007 Jan; 177(1):128-30. PubMed ID: 17162022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.